What You Need to Know About New Hepatitis C Drugs

According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead (NASDAQ: GILD  ) and Johnson & Johnson (NYSE: JNJ  ) .

Those two treatments, both of which won FDA approval late last year, posted significant sales during the first quarter. However, another new wave of promising hepatitis C treatments are awaiting FDA approval, suggesting there may be significant shifts in market share by the end of the year.

In the following slideshow, you'll learn how much Gilead and Johnson generated in revenue from their new drugs during the first quarter, and why AbbVie (NYSE: ABBV  ) and Bristol-Myers (NYSE: BMY  ) may win away market share later this year.

Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2926552, ~/Articles/ArticleHandler.aspx, 8/23/2014 1:34:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement